NCT06306170 Advanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART)
| NCT ID | NCT06306170 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS San Raffaele |
| Condition | Gynecologic Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-02-15 |
| Primary Completion | 2027-02-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2024-02-15 with a primary completion date of 2027-02-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational mono-institutional study. Patients with gynecologic tumors treated with advanced radiotherapy- Image Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Body Radiotherapy (SBRT)- will be included and toxicity and outcomes analyzed.
Eligibility Criteria
Inclusion Criteria: * gynecologic cancer patients * \>18 years old * treated with advanced radiotherapy techniques (IGRT, IMRT, SBRT) Exclusion Criteria: * other tumors * \> 90 years old
Contact & Investigator
andrei Fodor, MD
PRINCIPAL INVESTIGATOR
IRCCS San Raffaele Scientific Institute
Frequently Asked Questions
Who can join the NCT06306170 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 90 Years, studying Gynecologic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06306170 currently recruiting?
Yes, NCT06306170 is actively recruiting participants. Contact the research team at fodor.andrei@hsr.it for enrollment information.
Where is the NCT06306170 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06306170 clinical trial?
NCT06306170 is sponsored by IRCCS San Raffaele. The principal investigator is andrei Fodor, MD at IRCCS San Raffaele Scientific Institute. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.